Takeda Pharmaceutical Co Ltd Wave 1 Pipeline Opportunity Call - Part 2 - R&D Team Follow Up Call Transcript
(foreign language) Good morning. At this time, we would like to begin the event. I'll be moderating this session today from Takeda IR. My name is Iwamuro. Thank you for joining us. (Operator Instructions) Yes, we'd like to begin the session.
Before we start, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on Page 2 of today's presentation.
Now I'd like to begin the event. First, maribavir, soticlestat, and Orexin presentation will be done by our Takeda's development team. We'll be using the presentation material that we provided the other day. I hope you will have it on hand.
We will begin with the presentation on maribavir. [Sano-san],
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
